Here you will find companies that develop vaccines against SARS-CoV-2 or contribute to vaccine research.
For mucosal pathogens like SARS-CoV-2 mucosal immunity should be prominently considered. Without need for any gene modification, our proprietary microbial-display-system allows to use any bacteria as antigen carriers for the development of efficient mucosal vaccines.
Development of a COVID-19 subunit vaccine based on virus-like particles (VLP)
Development of RNA vaccines
Development of new compounds in the Covid-19 Therapeutics Accelerator with B. & M. Gates Foundation and other companies
Technology for the production of adenoviral vaccines. Assisting partner companies that develop adenoviral vaccines against the SARS-CoV-2 virus to safely produce adenoviral vectors
Development of mRNA vaccines
Part of the NIH-led initiative Accelerating COVID-19 Therapeutic Interventions and Vaccines (“ACTIV”), a public-private partnership aiming to develop a framework for prioritising vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes, and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics
Joined “COVID R&D”, the global crowdsourcing initiative among top pharmaceutical company R&D leaders aimed at facilitating therapies and vaccines against COVID-19, where we will be sponsoring the pre-clinical repurposing group to channel candidate molecules from consortium members or external sources to COVID R&D
Vaccine development based on peptides; Software and apps in the hospital environment, social distancing app; Development, peptide tools, peptide arrays for Eitopmapping, and cellular immune response, titer tests
Vaccine purification; Acute therapy
Vaccine development; Development of potential therapeutic agents
DNA production for vaccine production
Expression of antigens for vaccine development and expression of neutralizing antibodies using AAV vectors (planned)
Support pharma and biotech in the search for a vaccine, possible production of a vaccine in large quantities.
Production of more than 1000 tailor-made synthetic SARS-CoV-2 genes for universities, pharmaceutical and biotech companies. The demand for the DNA genetic code that codes for the virus envelope or genes is constantly increasing. Customers around the world are provided with much-needed custom virus constructs to accelerate the development of vaccines and therapeutics.
Provision of a Covid-19 vaccine for clinical trials in summer 2020